Therefore, it could be anticipated that METTL18 contributes to the progression of HER2-positive breast cancer; however, our clinical data indicate that METTL18 is not associated with the prognostic outcomes of HER2-positive breast cancer. Here, METTL18 is linked to breast cancer.